Veru (NASDAQ:VERU) Stock Rated Buy in New Coverage at Westpark Capital

Analysts at Westpark Capital assumed coverage on shares of Veru (NASDAQ:VERU – Get Free Report) in a research note issued to investors on Tuesday, MarketBeat reports. The brokerage set a “buy” rating on the stock.

VERU has been the subject of several other reports. Weiss Ratings upgraded Veru from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday. Wall Street Zen lowered shares of Veru from a “hold” rating to a “sell” rating in a report on Sunday, September 27th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $24.50.

Get Veru alerts:

Get Our Latest Analysis on VERU

Veru Stock Performance

Shares of VERU stock traded down $0.08 on Tuesday, hitting $2.47. The stock had a trading volume of 1,515,092 shares, compared to its average volume of 736,566. Veru has a 52-week low of $2.05 and a 52-week high of $7.33. The firm has a market capitalization of $42.11 million, a price-to-earnings ratio of -3.58 and a beta of -1.21. The stock’s 50 day moving average is $2.53 and its 200-day moving average is $2.53.

Veru (NASDAQ:VERU – Get Free Report) last announced its earnings results on Monday, August 10th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.02. Equities analysts expect that Veru will post -1.07 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. FNY Investment Advisers LLC bought a new stake in shares of Veru during the second quarter valued at about $328,000. Renaissance Technologies LLC bought a new stake in shares of Veru during the 1st quarter worth about $153,000. Finally, Royal Bank of Canada raised its position in shares of Veru by 69.3% during the 1st quarter. Royal Bank of Canada now owns 12,239 shares of the company’s stock worth $27,000 after buying an additional 5,008 shares in the last quarter. Institutional investors own 47.16% of the company’s stock.

About Veru

(Get Free Report)

Veru Inc is a biopharmaceutical company focused on developing medicines for obesity, metabolic disorders and cancer. Its development programs are designed to address weight management, preservation of muscle mass during weight loss and treatment of certain hormone-sensitive cancers.

The company’s lead investigational product, enobosarm, is an oral selective androgen receptor modulator being evaluated for its potential to promote or preserve lean muscle while supporting weight loss. Veru has also developed oncology candidates, including sabizabulin, an oral microtubule disruptor studied in cancer indications, and other hormone-directed therapies.

Veru was formerly known as The Female Health Company and historically developed and commercialized the FC2 Female Condom, a female-controlled barrier contraceptive and sexually transmitted infection prevention product distributed in the United States and international markets.

Featured Articles

• Five stocks we like better than Veru
• Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI
• Lamb Weston’s Turnaround Is Starting to Look Real
• These 3 Stocks Got the Most Love From Analysts in September
• Record French Debt Could Create Opportunities for U.S. Market Operators

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.